GSK Breast
21 Dec 2020
GSK Breast
NCT02964507
A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer
GlaxoSmithKline
Cancer Type | Breast |
---|---|
Trial Type | Treatment |
Phase | Phase I, Phase II |
Age Range | 18 years and older |
Sex | Female |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
Anticipated Start Date | 2017-02-02 |
Anticipated End Date | 2022-09-15 |
Hospital | Flinders Medical Centre |
---|---|
Clinical Trial Coordinator | Alex Scott-Hoy |
alex.scott-hoy@sa.gov.au | |
Phone | 08 8204 4830 |
Principal Investigator | Professor Bogda Koczwara |
Recruitment Status | Recruiting |